Pharmacokinetics of single-dose intravenous levetiracetam administration in normal dogs

被引:23
作者
Dewey, Curtis W. [1 ]
Bailey, Kerry S. [1 ]
Boothe, Dawn M. [2 ]
Badgley, Britton L. [1 ]
Cruz-Espindola, Crisanta [2 ]
机构
[1] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA
[2] Auburn Univ, Dept Anat Physiol & Pharmacol, Coll Vet Med, Auburn, AL 36849 USA
关键词
seizures; intravenous; levetiracetam;
D O I
10.1111/j.1476-4431.2008.00294.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
To determine plasma pharmacokinetics of levetiracetam after a single intravenous dose (60 mg/kg) in normal dogs using a high-performance liquid chromatography assay validated for canine plasma. Pharmacokinetic study. A university-based canine research facility. Six healthy adult dogs. Intravenous drug administration, multiple blood sample procurement. There were no obvious adverse effects associated with the intravenous (IV) bolus administration of levetiracetam in any of the dogs. Plasma levetiracetam concentrations remained above or within the reported therapeutic range for humans (5-45 mu g/mL) for all dogs, for all time periods evaluated. Mean and median (in parentheses) values for pharmacokinetic parameters included the following: maximum plasma concentration, 254 mu g/mL (254 mu g/mL); half-life, 4.0 hours (4.0 hours); volume of distribution at steady state, 0.48 L/kg (0.48 L/kg); clearance, 1.4 mL/kg/min (1.5 mL/kg/min); and median residence time, 6.0 hours (6.0 hours). In normal dogs, a 60 mg/kg IV bolus dose of levetiracetam is well tolerated and achieves plasma drug concentrations within or above the therapeutic range reported for humans for at least 8 hours after administration. Based on the favorable pharmacokinetics and tolerability demonstrated for IV levetiracetam in this study, in addition to previously demonstrated efficacy of oral levetiracetam, IV levetiracetam may be a useful treatment option for emergency management of canine seizure activity.
引用
收藏
页码:153 / 157
页数:5
相关论文
共 26 条
[1]  
BAILEY KS, 2008, J AM VET MED ASSOC, P867
[2]  
Bateman SW, 1999, J AM VET MED ASSOC, V215, P1463
[3]   New antiepileptic drugs [J].
Bazil, CW .
NEUROLOGIST, 2002, 8 (02) :71-81
[4]   Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog [J].
Benedetti, MS ;
Coupez, R ;
Whomsley, R ;
Nicolas, JM ;
Collart, P ;
Baltes, E .
XENOBIOTICA, 2004, 34 (03) :281-300
[5]   Anticonvulsant therapy in dogs and cats [J].
Dewey, Curtis W. .
VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE, 2006, 36 (05) :1107-+
[6]   Rapid onset of action of levetiracetam in refractory epilepsy patients [J].
French, J ;
Arrigo, C .
EPILEPSIA, 2005, 46 (02) :324-326
[7]   Use of levetiracetarn in special populations [J].
French, J .
EPILEPSIA, 2001, 42 :40-43
[8]  
HANON E, 2000, SEIZURE, V10, P287
[9]   Safety profile of levetiracetam [J].
Harden, C .
EPILEPSIA, 2001, 42 :36-39
[10]   Levetiracetam: A novel antiepileptic drug [J].
Hovinga, CA .
PHARMACOTHERAPY, 2001, 21 (11) :1375-1388